Aug. 13 (Bloomberg) -- Vascular Biogenics, the Israeli biotechnology company that went public in the U.S. last month, canceled the initial public offering after a substantial investor failed to pay for the shares it agreed to buy, according to a statement Aug. 8. Bloombergs Leslie Picker reports on Market Makers. (Source: Bloomberg)